BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers.
BridgeBio Pharma has 80 open roles live as of 5 September 2026. 48% of BridgeBio Pharma's open roles are remote, placing BridgeBio Pharma in ReqHunt Remote Index tier R2 (Distributed), and BridgeBio Pharma hires most in Remote (United States) (35 roles). These figures are read directly from BridgeBio Pharma's Greenhouse careers page and were last checked on 5 September 2026.
How the ReqHunt Remote Index works — the four bands, the 10-role floor, why hybrid is excluded, and why companies with incomplete location data are withheld rather than scored low.
Read straight from BridgeBio Pharma's careers page (greenhouse), tracked since August 2026. Refreshed every hour. “No longer listed” means the role has left the company's careers feed. That can mean filled, cancelled or withdrawn — the feed does not say which.
Data source: ReqHunt — read from BridgeBio Pharma's Greenhouse careers page on 5 September 2026. https://reqhunt.com/company/bridgebio-pharma
Structured data for LLMs and AI crawlers is available at /company/bridgebio-pharma.md.
Remote roles are counted here too, by the scope they are open to. 15 of 80 live roles carry no location or remote scope we can resolve, so they are not listed below.
Peak sales estimates include currently projected revenues from products with regulatory approval (Attruby in the US and Beyonttra outside of the US) and investigational product candidates, including Encaleret, BBP-418, and Infigratinib, which have not yet received FDA or other regulatory approval.
As of 5 September 2026, BridgeBio Pharma ranks 18th in the ReqHunt most remote jobs ranking with a Remote Index of R2.
Track BridgeBio Pharma and thousands of other companies — new roles the moment they appear on the careers page.
Join free